| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$490,841 ) |
| | 2025 | 2020 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 14 | NIH | 10/1/2024 | -$490,841 |
|
| Issue Date FY: 2024 ( Subtotal = -$88,686,629 ) |
| | 2024 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UH3HL147011 | 1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis | 000 | 2 | NIH | 12/12/2023 | -$1,064,614 |
| | 2024 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109 | KING | USA | F32CA243286 | Investigating the Role of DNA Repair Mutations in Prostate Cancer Initiation, Progression, and Susceptibility to Targeted Therapies | 000 | 3 | NIH | 4/12/2024 | -$3,051 |
| | 2024 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 15 | NIH | 10/23/2023 | -$6,743,674 |
| | 2024 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 001 | 15 | NIH | 10/23/2023 | -$38,278,635 |
| | 2024 | 2020 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 14 | NIH | 10/23/2023 | -$37,626,512 |
| | 2024 | 2020 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 14 | NIH | 10/23/2023 | -$5,062,634 |
| | 2024 | 2019 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | OT3HL151434 | The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option | 004 | 1 | NIH | 2/8/2024 | $92,489 |
| | 2024 | 2019 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | OT3HL151434 | The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option | 003 | 1 | NIH | 2/8/2024 | $92,489 |
| | 2024 | 2019 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109 | KING | USA | OT3HL151434 | The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option | 000 | 1 | NIH | 1/30/2024 | -$92,489 |
|
| Issue Date FY: 2023 ( Subtotal = -$67,673,560 ) (Continued on the next page) |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 002 | 16 | NIH | 12/19/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 002 | 16 | NIH | 12/19/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 001 | 16 | NIH | 12/13/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 001 | 16 | NIH | 12/13/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 006 | 16 | NIH | 2/7/2023 | -$3,872,089 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 006 | 16 | NIH | 2/7/2023 | -$1,564,038 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 000 | 16 | NIH | 11/30/2022 | -$241,853 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R03CA267113 | Type II diabetes, related biomarkers and medications, and ovarian cancer risk | 001 | 1 | NIH | 5/15/2023 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 002 | 16 | NIH | 5/2/2023 | -$6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 002 | 16 | NIH | 5/2/2023 | -$10,347 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 008 | 16 | NIH | 6/21/2023 | $10,347 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 007 | 16 | NIH | 6/21/2023 | $6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 004 | 16 | NIH | 5/15/2023 | -$10,347 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 005 | 16 | NIH | 5/15/2023 | -$6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31CA260932 | Necrosis-mediated circulating tumor cell dissemination | 003 | 1 | NIH | 5/15/2023 | -$448 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31CA260932 | Necrosis-mediated circulating tumor cell dissemination | 001 | 1 | NIH | 3/29/2023 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R21AI169085 | Integrating T cell receptor features with gene expression profiles to define T cell specificity and differentiation | 000 | 1 | NIH | 10/14/2022 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F32CA254805 | Reactivation of an early embryonic program in FSHD and cancer | 002 | 2 | NIH | 5/15/2023 | -$2,026 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 002 | 3 | NIH | 11/28/2022 | -$22,711 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 003 | 3 | NIH | 11/28/2022 | -$28,853 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 001 | 3 | NIH | 11/28/2022 | -$89,755 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31NS118844 | Molecular mechanisms underlying neuronal integrity | 002 | 2 | NIH | 5/15/2023 | -$2,491 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01HL147324 | Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | 002 | 3 | NIH | 5/16/2023 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31AI150163 | Evolutionary dynamics of antibody affinity maturation | 001 | 3 | NIH | 5/15/2023 | -$1,526 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 16 | NIH | 12/13/2022 | -$2,672,807 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$2,204,970 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$3,817,177 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$125,000 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$125,000 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31NS118958 | Defining the role of C. elegans Parkin/PDR-1 in glial engulfment of neuron fragments | 002 | 2 | NIH | 5/15/2023 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 000 | 2 | NIH | 11/28/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI054423 | Genetic requirements of Helicobacter pylori infection | 002 | 17 | NIH | 6/15/2023 | -$1,829 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | K99NS121595 | Mechanisms of Target-Specific Axon Regeneration | 003 | 1 | NIH | 12/22/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | K99NS121595 | Mechanisms of Target-Specific Axon Regeneration | 000 | 1 | NIH | 11/30/2022 | -$2,958 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 000 | 2 | NIH | 11/16/2022 | -$82,644 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R21NS124191 | Discovery of sensorimotor connectivity mechanisms in a continuous topographic map | 000 | 1 | NIH | 11/15/2022 | -$4,431 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 026 | 16 | NIH | 7/20/2023 | -$500,081 |
|
